Q3

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), an immunology and inflammation company focused on developing therapies that promote immune tolerance, and Clywedog Therapeutics, Inc. (“Clywedog”), a private company advancing novel breakthrough medicines in diabetes, announce that they have entered into a definitive merger agreement to combine in an all-stock transaction. The newly combined company will

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases Read More »

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) (“MIRA” or the “Company”), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, announces that it has completed its acquisition of SKNY Pharmaceuticals, Inc. (“SKNY”). As part of the transaction, SKNY fulfilled all closing obligations, contributing $5 million in marketable securities to MIRA, further strengthening

MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals Read More »

Hot Topics in Healthcare: M&A and Private Equity Trends

The next phase of healthcare M&A is likely to shift beyond traditional provider roll-ups toward specialized services and technology integration. Investors are zeroing in on contract development and manufacturing organizations and outsourced pharmaceutical services, recognizing the scalability of these models. Medical equipment service companies—especially those maintaining robotic systems and specialized hospital technologies—are poised for consolidation.

Hot Topics in Healthcare: M&A and Private Equity Trends Read More »

Further Consolidation May Loom as Medicare’s Bidding Program Pressures Small DME Providers

The return of Medicare’s competitive bidding program will further consolidate the home medical equipment (HME) industry, according to 90% of respondents to a recent HME Newspoll. And that’s the goal, they say. Respondents say the program is structured to award bids to fewer providers at lower reimbursement rates, shrinking the industry with each round. “Independent

Further Consolidation May Loom as Medicare’s Bidding Program Pressures Small DME Providers Read More »

A Health System Ambulatory Boom Is Coming

Ambulatory care has been on the agenda for decades, but today it has become a strategic imperative for health system C-suites. Rising costs, value-based payment models, and shifting patient expectations have pushed ambulatory growth from a “nice to have” into the center of the C-suite playbook. Executives increasingly view surgery centers, primary care networks, urgent

A Health System Ambulatory Boom Is Coming Read More »

Scroll to Top